about
The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic SyndromeRole of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee RecommendationsOmega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Using apolipoprotein B to manage dyslipidemic patients: time for a change?Low literacy is associated with uncontrolled blood pressure in primary care patients with hypertension and heart disease.Statin-induced myopathy: a review and update.Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.Managing dyslipidemia in chronic kidney disease.Evidence-based management of statin myopathy.An assessment by the Statin Intolerance Panel: 2014 update.Risk for myopathy with statin therapy in high-risk patients.Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.Development and evaluation of a medication counseling workshop for physicians: can we improve on 'take two pills and call me in the morning'?Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY.Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT.Usefulness of omega-3 fatty acids and the prevention of coronary heart disease.Statin safety: lessons from new drug applications for marketed statins.Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly.Secondary prevention of coronary artery disease with omega-3 fatty acids.The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial.Hypertriglyceridemia and cardiovascular risk reduction.Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease.Patient literacy and question-asking behavior during the medical encounter: a mixed-methods analysis.Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.Initiating statins in the elderly: the evolving challenge.Effects of niacin on glucose control in patients with dyslipidemia.Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.Chronic kidney disease and statins: improving cardiovascular outcomes.The importance of non-HDL cholesterol reporting in lipid management.Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math.
P50
Q28082734-E5DA012B-9F40-4F16-9B2E-E9587E440A41Q29994487-95171C8C-B2E7-4628-B592-DCFE87D88893Q30235305-27A0A713-82FD-4507-B990-C8284494067AQ30596281-A33C30BF-E9B8-47A9-A4ED-3BDE0B87E582Q30848030-CAB36D28-2DEC-4AD6-8B63-821F8D08BA50Q33578422-A020F91A-596D-44BC-ADFA-35E775DCF595Q33665495-669405C4-F4E2-4AEC-ACA3-45C0486583C5Q33765072-DE04F9B6-EA4A-4E26-9626-F46324D4AAFFQ33820011-0F1500A8-CD40-41BA-9853-81104E0BE12EQ33915728-95D34F47-04FB-42ED-94E6-BA908D2BB88BQ34166144-40DD9E14-FF54-4735-921E-095F50429DCEQ34294996-AB4F8718-BB85-4237-9949-5597629DA8ACQ34439436-F843586C-A633-4F78-90CA-526AD61B079CQ34453402-0FFE376E-B7B9-4DF1-8DD1-32586263132BQ34506362-AAB7C8F8-6D71-48FA-B6F3-4323093F60EFQ34593333-65C0DF2C-A09B-4FBB-8AFB-7112DF676B31Q34621494-7495819D-4A93-43ED-9DC6-C3FB513797FBQ34661723-31A16C26-9CF6-467F-92EA-D83C18E4DAB5Q35080026-D6D3CB0D-49FF-4AAC-9F14-EF9BDE5A123EQ35194386-9B651362-7EEE-4012-9709-151652723199Q35208597-CACF8C93-2C70-418C-BD7E-5DBEC70C00F5Q35927772-C1D2D849-D22A-4B30-A79B-CFFCC1B9D34BQ35927776-AE4B70F1-6032-4312-9B80-DF91CA7D0AC4Q36323416-54BB02EB-8FD8-4F40-A109-0A1FEA323B91Q36438045-3617E460-4FA2-4F71-95E0-DD33865036E0Q36438054-649C2065-2ED1-4980-92B5-878A5A77ED61Q36475343-4133FE8F-A6AC-4A61-A9CB-7EFEFCDC249EQ36571153-9C722A82-6B6A-49FE-966E-DA676FE1D13CQ36592579-27A8FDA5-B7D3-4DB1-8D8C-537931FA6800Q36809006-CF30A39A-C955-4DC4-9B3C-BCD0EF8F2244Q36909865-27F0305C-7DCF-4A9B-8381-62EA397B66D4Q36945230-D6B83005-8227-4781-8789-7FABDC4420BAQ36974893-7A8025B5-717F-4970-BE69-6446C53524A7Q37034257-AEC86833-B9AB-47A8-9005-0D55209CCDCAQ37100827-116D34F5-A6A6-433A-A850-9A2C861216C8Q37125028-54EBC25D-2B8C-4888-A678-6574EBF18C36Q37183196-8D3B4863-DC0B-48B6-91FF-52AA7A514C33Q37509290-D3382895-2F7E-4AB6-8F3C-5C4A220F504DQ37835398-567F993C-248C-4FD4-9679-A06D666E5C6DQ37903468-BAF3B254-01C2-4DAC-A9CF-F8AEE62A02C4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Terry A Jacobson
@nl
Terry A Jacobson
@sl
Terry A. Jacobson
@en
Terry A. Jacobson
@es
type
label
Terry A Jacobson
@nl
Terry A Jacobson
@sl
Terry A. Jacobson
@en
Terry A. Jacobson
@es
prefLabel
Terry A Jacobson
@nl
Terry A Jacobson
@sl
Terry A. Jacobson
@en
Terry A. Jacobson
@es
P106
P1153
7005348111
P31
P496
0000-0002-9926-2179